Clinical Trial Update: Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/Rearrangements [Phase 2]

View source ↗

Summary

This Phase 2 trial of pemigatinib for advanced intrahepatic cholangiocarcinoma with FGFR2 fusions has been terminated. The study status indicates it did not pro…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intrahepatic Cholangiocarcinoma

Drugs mentioned

• Pemazyre (pemigatinib)

Snippet

Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Conditions: Intrahepatic Cholangiocarcinoma, FGFR2 Gene Mutation | Phase 2 | Status: TERMINATED